MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

Open AllClose All
  BD2K Research Education Curriculum Development: Data Science Overview for Biomedical Scientists (R25) (Deadline: 12/7/16)

BD2K Research Education Curriculum Development: Data Science Overview for Biomedical Scientists (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this BD2K R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in Big Data Science to augment current institutional curricula for the training of pre-doctoral level biomedical scientists and provide concentrated instruction in the tools, approaches and quantitative analysis concepts in data science. To facilitate the integration of data science into biomedical curricula nationally, this FOA seeks to support a cohort of institutions that will work collaboratively and collectively to produce curricular materials that are findable, accessible, interoperable, and reusable (FAIR).

Applications due December 7, 2016

  Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01) (Deadline: 12/15/16)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01)

As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.

Applications due December 15, 2016

  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01) (Deadline: 1/7/17)

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Applications due January 7, 2017

  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21) (Deadline: 1/7/17)

High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

Support will be provided to replicate the impact of the natural product on the biological signature (i.e., mechanism of action) when used by humans. In addition, support will be provided to demonstrate an association between the change in the biological signature and improvement in clinical outcomes. This FOA is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted.

Applications due January 7, 2017

  Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (R01) (Deadline: 1/7/17)

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (R01)

This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers. Studies may consider changing needs that occur across time points and disease progression, as well as ways in which EOLPC and planning can adapt to meet these changing needs. Childhood cancers are not of interest for the purposes of this FOA.

NCI: Examine the unique physical and psychosocial issues related to EOLPC that may present among adults with advanced rare cancers (those with an incidence of fewer than 150 per million per year or approximately 40,000 cases or fewer) and their family/informal caregivers, including but not limited to psychological distress, prognostic uncertainty, social isolation, decisional regret, and decision-making in an emotional and ambiguous context.

Types of studies may include innovative methods or approaches such as qualitative, mixed methods, observational, quasi-experimental, and experimental with focus on individual- and family-centered outcomes. It is strongly encouraged that the investigative teams be interdisciplinary and include nurse scientists and early stage investigators. Investigators are also encouraged to consider using existing palliative care research networks, such as the Palliative Care Research Cooperative Group and other multisite data resources and research networks such as the National Cancer Institute Community Oncology Research Program, to carry out small, multi-site trials when appropriate.

Applications due January 7, 2017

  Limited Competition: The Chernobyl Tissue Bank – Coordinating Center (U24) (Deadline: 1/20/17)

Limited Competition: The Chernobyl Tissue Bank – Coordinating Center (U24)

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center.

The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

Applications due January 20, 2017

  National Cancer Institute Program Project Applications (P01) (Deadline: 1/25/17)

National Cancer Institute Program Project Applications (P01)

With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Applications due January 25, 2017

  Support of Competitive Research (SCORE) Research Advancement Award (SC1) (Deadline: 1/25/17)

Support of Competitive Research (SCORE) Research Advancement Award (SC1)

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (BS or BA) and/or graduate students (MS or PhD) and have received less than six million dollars per year of NIH R01 support (total costs) in each of the last two fiscal years.

Applications due January 25, 2017

  Support of Competitive Research (SCORE) Pilot Project Award (SC2) (Deadline: 1/25/17)

Support of Competitive Research (SCORE) Pilot Project Award (SC2)

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and research capacity of institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (BS or BA) and/or graduate students (MS or PhD) and have received less than six million dollars per year of NIH R01 support (total costs) in each of the last two fiscal years.

Applications due January 25, 2017

  Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015, 2016, and 2017 (P50) (Deadline: 1/27/17)

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015, 2016, and 2017 (P50)

This Funding Opportunity Announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). For the purpose of this funding announcement, cancers derived from the same organ system (i.e., group of organs that perform common function) are considered related. Examples of such organ systems include gastro-intestinal, endocrine, circulatory, and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems.

For example, a SPORE may focus on cancers caused by the same infectious agent, or sustained and promoted by dysregulation of a common signaling pathway. SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research projects with other institutions.

The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the project period of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Enhancement Program to foster careers in translational research related to the focus of the SPORE.

Applications due January 27, 2017

  NCI Research Specialist (Core-based Scientist) Award (R50) (Deadline: 2/2/17)

NCI Research Specialist (Core-based Scientist) Award (R50)

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Applications due February 2, 2017

  NCI Research Specialist (Laboratory-based Scientist) Award (R50) (Deadline: 2/2/17)

NCI Research Specialist (Laboratory-based Scientist) Award (R50)

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Applications due February 2, 2017

  Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01) (Deadline: 2/5/17)

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to develop and implement effective interventions to address health disparities among U.S. immigrant populations.

Applications due February 5, 2017

  Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01) (Deadline: 2/5/17)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.

Applications due February 5, 2017

  Research Aimed at Novel Behavioral Targets to Improve Adolescent Substance Abuse Treatment and Prevention Interventions (R01) (Deadline: 2/5/17)

Research Aimed at Novel Behavioral Targets to Improve Adolescent Substance Abuse Treatment and Prevention Interventions (R01)

This Funding Opportunity Announcement (FOA) is part of a trans-NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to inform the generation and refinement of novel targets for substance abuse treatment and prevention interventions, modules or adjuncts to existing treatments and prevention interventions that seek to target and modulate behavioral or neurobehavioral processes (e.g., impulsivity, risk-taking propensity, sensation and novelty seeking, distress tolerance, delay discounting, self-regulation, stress reactivity) in adolescents. Additionally, this FOA will encourage studies to include theoretical links that explore the relationship(s) between neural circuitry and treatment and prevention effects, and in particular, how behavioral targets might be affected by treatment and prevention interventions, and how that might be used to improve targeted treatment and prevention intervention development, that translate to reduced morbidity and mortality.

Components of Participating Organizations:
National Institute on Drug Abuse (NIDA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Cancer Institute (NCI)

Applications due February 5, 2017

  Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R21) (Deadline: 2/16/17)

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate innovative exploratory and developmental research to develop and test feasibility of effective interventions to address health disparities among U.S. immigrant populations.

Applications due February 16, 2017

  Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R21) (Deadline: 2/16/17)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.

Applications due February 16, 2017

  Examination of Survivorship Care Planning Efficacy and Impact (R01) (Deadline: 2/5/17)

Examination of Survivorship Care Planning Efficacy and Impact (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest.

Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning.

The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 5, 2017

  Population-Based Research to Optimize the Screening Process (PROSPR) (UM1) (Deadline: 2/9/17)

Population-Based Research to Optimize the Screening Process (PROSPR) (UM1)

The overall goal for PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple, heterogeneous healthcare environments in the United States. Therefore, the research programs proposed must cover long-term observations of diverse cohorts of patients who are eligible for screening. In addition to observational research to evaluate factors that affect the quality of the screening process for the selected cancer type, these programs should also develop and pilot-test interventions aimed at improving the screening process for that cancer.

It is expected that this FOA will support one PROSPR Research Center for each of the three cancer types: cervical, colorectal, and lung cancer. Each proposed Research Center must be entirely focused on screening for one of these three eligible cancer types.

In addition, PROSPR Research Centers to be proposed must be able to study the cancer screening processes in at least three different healthcare systems. Therefore, appropriate collaborative arrangements with providers of screening/diagnostic services are required.

Applications due February 9, 2017

  Coordinating Center for Population-Based Research to Optimize the Screening Process (PROSPR) (U24) (Deadline: 2/9/17)

Coordinating Center for Population-Based Research to Optimize the Screening Process (PROSPR) (U24)

The overall goal for the PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple healthcare environments in the United States.

The intent of this FOA is to fund a single Coordinating Center that will support a network of three PROSPR Research Centers (PRCs; one each focused on cervical, colorectal, and lung cancer). Specifically, the Coordinating Center will facilitate the development of common measures across cancer types for (1) system-level factors that may impact the cancer screening process, and (2) quality of screening. It will also coordinate PROSPR network research projects that include more than one cancer type. Finally, the Coordinating Center will be responsible for developing and implementing a process for PROSPR data access and sharing with qualified investigators outside of the PROSPR network.

Applications due February 9, 2017

  Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) (Deadline: 2/15/17)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data.

This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Applications due February 15, 2017

  Examination of Survivorship Care Planning Efficacy and Impact (R21) (Deadline: 2/16/17)

Examination of Survivorship Care Planning Efficacy and Impact (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest.

Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 16, 2017

  Palliative Care Needs of Individuals With Rare Advanced Diseases and Their Family Caregivers (R21) (Deadline: 2/16/17)

Palliative Care Needs of Individuals With Rare Advanced Diseases and Their Family Caregivers (R21)

This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers. Studies may consider changing needs that occur across time points and disease progression, as well as ways in which EOLPC and planning can adapt to meet these changing needs. Childhood cancers are not of interest for the purposes of this FOA.

NCI: Examine the unique physical and psychosocial issues related to EOLPC that may present among adults with advanced rare cancers (those with an incidence of fewer than 150 per million per year or approximately 40,000 cases or fewer) and their family/informal caregivers, including but not limited to psychological distress, prognostic uncertainty, social isolation, decisional regret, and decision-making in an emotional and ambiguous context.

Types of studies may include innovative methods or approaches such as qualitative, mixed methods, observational, quasi-experimental, and experimental with focus on individual- and family-centered outcomes. It is strongly encouraged that the investigative teams be interdisciplinary and include nurse scientists and early stage investigators. Investigators are also encouraged to consider using existing palliative care research networks, such as the Palliative Care Research Cooperative Group and other multisite data resources and research networks such as the National Cancer Institute Community Oncology Research Program, to carry out small, multi-site trials when appropriate.

Applications due February 16, 2017

  Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) (Deadline: 2/28/17)

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) (Deadline: 2/28/17)

Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  NCI Small Grants Program for Cancer Research (NCI Omnibus R03) (Deadline: 2/28/17)

NCI Small Grants Program for Cancer Research (NCI Omnibus R03)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Applications due February 28, 2017

  Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01) (Deadline: 2/28/17)

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application.

This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Applications due February 28, 2017

  Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) (Deadline: 4/11/17)

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.

The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Applications due April 11, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Open AllClose All
  Breast Cancer Research Program (BCRP) – Breakthrough Award – Levels 3 and 4 (Deadline: 12/8/16)

Breast Cancer Research Program (BCRP) – Breakthrough Award – Levels 3 and 4

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:

Impact
Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

Research Scope
Research proposed under this award mechanism may be small - to large - scale projects, at different stages of idea and research development.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

Funding Level 3
Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.

Funding Level 4
Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects.

Considering the current breast cancer landscape and the BCRP's vision to end breast cancer, each FY16 Innovator Award application must address one or more of the following overarching challenges. Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application.

  • Prevent breast cancer (primary prevention);
  • Identify what makes the breast susceptible to cancer development
  • Determine why some, but not all, women get breast cancer;
  • Distinguish aggressive breast cancer from indolent cancers;
  • Conquer the problems of over-diagnosis and overtreatment;
  • Identify what drives breast cancer growth; determine how to stop it;
  • Identify why some breast cancers become life - threatening metastasis;
  • Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence;
  • Revolutionize treatment regimens by replacing interventions that have life-threatening toxicities with ones that are safe and effective; and
  • Eliminate the mortality associated with metastatic breast cancer.

Pre-Applications due September 14, 2016

Applications due December 8, 2016

Foundations & Organizations

Open AllClose All
  Mary Kay Foundation | Cancer Research Grant Program (Pre-Application Deadline: 12/12/16)

Mary Kay Foundation | Cancer Research Grant Program

The Mary Kay Foundation is a funding source for cancer research and is currently accepting applications for innovative grants for translational research in ovarian, uterine, breast, or cervical cancer. The foundation anticipates funding between 10 and 15 grants, but only one application can be submitted by MCW. The award is $100,000 for a two-year period, including indirect costs which cannot exceed 15%.

Due to the limit of one grant application per institution, the MCW Cancer Center Director's Council will select a final candidate to submit the full proposal to the Mary Kay Foundation Cancer Research Grant Program. If interested in applying, please see instructions below:

Pre-Application Process

Submit the following materials by email to Terri Misorski, Grants Operations Coordinator, (tmisorsk@mcw.edu), by noon (12 p.m. CST) on Monday, December 12, 2016:

  1. Letter of Nomination from senior or supervising faculty member, to be addressed to the MCW Cancer Center Director's Council.
  2. Written approval from nominee's department chair.
  3. Brief description from the nominee of his/her proposed research project (two-page maximum).
  4. Nominee's NIH biosketch.

Deadlines

  • Pre-application materials are due to Terri Misorski by noon (12 p.m. CST) on Monday, December 12, 2016.
  • Applicants will be notified of the selection by Friday, December 23, 2016.
  • Full application for the final candidate will be due to the Mary Kay Foundation by 5 p.m. CST on February 3, 2017.
  American Urological Association (AUA) Urology Care Foundation (Deadline: 1/15/17)

American Urological Association (AUA) Urology Care Foundation

These awards provide motivated and exceptional urology residents with mentored training to prepare them for careers that include urologic research. Residents conduct research under the direction of an accomplished mentor. Conducting urologic research is an exciting and vital activity for medical professionals. Research training during urology residency provides residents with exposure to this potential career path and experience to enable them to continue their development towards becoming independent investigators. Importantly, residency research training has the potential to address the critical and increasing shortfall of urology surgeon-scientists and to play a key role in departmental and institutional contributions to science and to improving patients' lives through research.

Applications due January 15, 2017

  Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer | American Gastroenterological Association (AGA) – AGA Research Foundation (Deadline: 1/20/17)

Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer | American Gastroenterological Association (AGA) – AGA Research Foundation

This award is for a young investigator, instructor, research associate or equivalent who currently holds a federal or non-federal career development award devoted to conducting research related to digestive cancer. The objective is to support young investigators conducting research relevant to the pathogenesis, prevention, diagnosis, or treatment of digestive cancer. The award is intended to supplement existing career development funding

Applications due January 20, 2017

  SFA Research Grants | Sarcoma Foundation of America (SFA) (Deadline: 1/31/17)

SFA Research Grants | Sarcoma Foundation of America (SFA)

The SFA has developed a program to provide grants to investigators interested in translational science Sarcoma research. Funding is available in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human Sarcomas.

In accordance with the mission of the Foundation, research involving the development of novel agents against Sarcoma, or research that could potentially lead to the development of novel agents against Sarcoma, is eligible for this funding. The SFA strongly prefers and will give special consideration to applications that focus on the following areas:

  • Omic characterization of sarcomas and definition of novel targets
  • Omic patterns of sensitivity and resistance to existing agents
  • Systematic therapy combinations
  • Immunotherapy

In compliance with IRS instructions, grants cannot fund clinical trials, but all other areas of research can be considered for funding.

Applications due January 31, 2017

  The National Pacreas Foundation (Deadline: 1/31/17)

The National Pacreas Foundation

The National Pancreas Foundation (NPF) is a private, non-profit organization established to support the funding of research related to pancreatic diseases. It also provides support for the men, women, and children who are suffering from diseases of the pancreas. The research must be in the field of pancreatic diseases. Studies intended to advance knowledge in the areas of pancreatic carcinoma, and all forms of pancreatitis would be the closest to the areas of interest of the NPF. Studies more closely related to diabetes will not be accepted.

Applications due January 31, 2017

  Elsa U. Pardee Foundation (Deadline: 2/1/17)

Elsa U. Pardee Foundation

The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Applications due February 1, 2017

  Lasker Awards | Lasker Foundation, Albert and Mary (Deadline: 2/1/17)

Lasker Awards (Lasker Foundation, Albert and Mary)

The Lasker Awards are among the most respected science prizes in the world. Since 1945, the Awards Program has recognized the contributions of scientists, physicians, and public servants who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of human disease.

The Albert Lasker Basic Medical Research Award honors scientists whose fundamental investigations have provided techniques, information, or concepts contributing to the elimination of major causes of disability and death.

The Lasker~DeBakey Clinical Medical Research Award honors investigators whose contributions have improved the clinical treatment of patients.

The Lasker~Koshland Special Achievement Award in Medical Science honors scientists whose contributions to research are of unique magnitude and have immeasurable influence on the course of science, health, or medicine, and whose professional careers have engendered within the biomedical community the deepest feelings of awe and respect.

The Lasker~Bloomberg Public Service Award honors men and women who have helped make possible the federal legislation and funding that supports research, and who have created public communication, public health, and advocacy programs of major importance.

Applications due February 1, 2017

  Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma (Deadline: 3/1/17)

Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma

The Leukemia & Lymphoma Society (LLS) and the Babich Family Foundation/RUNX1 Research Program are partnering to launch a competitive grant to advance new therapies for, and greater understanding of familial platelet disorders associated with RUNX1 mutations that lead to acute myelogenous leukemia. The program is focused on addressing translational research with a total of $1.8 million; 3 grants will be awarded up to $600,000 each. The applications will be evaluated by a dedicated team of experts and ranked separately from our normal Leukemia and Lymphoma TRP applications.

Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.

This program is intended to provide support over an initial three-year period. Two additional years may be available through the competitive, peer-reviewed TRP Renewal process to solidify progress made in the initial award and further support a clinical trial. To be considered for a TRP renewal award, a clinical protocol for a Phase I or Phase II clinical trial based on the initial Translational Research Program grant must be submitted to the institution's IRB for approval and the work must be a direct result of the funded TRP award.

Applications due March 1, 2017

  Distinguished Scientist Award (DSA) | The Sontag Foundation (Deadline: 3/15/17)

Distinguished Scientist Award (DSA) | The Sontag Foundation

This award seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer. Applicant's career track and proposed research should demonstrate potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Applications due March 15, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Neuroendocrine Tumor Research Foundation-AACR Grant (Deadline: 12/13/16)

Neuroendocrine Tumor Research Foundation-AACR Grant

The Neuroendocrine Tumor Research Foundation-AACR Grant represents a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to neuroendocrine tumor research.

Applications due December 13, 2016

  Biomedical Research Grant (RG) | American Lung Association (ALA) (Deadline: 12/15/16)

Biomedical Research Grant (RG) | American Lung Association (ALA)

This grant is a mentored award meant to provide seed monies to junior investigators on the path to independence for researching the mechanisms of lung disease and general lung biology.

The Lung Association is particularly interested in highly meritorious research projects consistent with our strategic imperatives:

  • Defeat lung cancer
  • Improve the air we breathe so it will not cause or worsen lung disease
  • Reduce the burden of lung disease on patients and their families
  • Eliminate tobacco use and tobacco-related lung diseases

Applications due December 15, 2016

  Clinical Patient Care Research Grant (CG) | American Lung Association (ALA) (Deadline: 12/15/16)

Clinical Patient Care Research Grant (CG) | American Lung Association (ALA)

This grant is a mentored award is meant to provide seed monies to junior investigators on the path to independence for conducting trials for the improvement of patient care and treatment for lung disease.

The Lung Association is particularly interested in highly meritorious research projects consistent with our strategic imperatives:

  • Defeat lung cancer
  • Improve the air we breathe so it will not cause or worsen lung disease
  • Reduce the burden of lung disease on patients and their families
  • Eliminate tobacco use and tobacco-related lung diseases

Applications due December 15, 2016

  Dalsemer Research Grant (DA) | American Lung Association (ALA) (Deadline: 12/15/16)

Dalsemer Research Grant (DA) | American Lung Association (ALA)

This grant is a mentored award meant to provide seed monies to junior investigators on the path to independence for researching the mechanisms and biology of interstitial lung disease.

The Lung Association is particularly interested in highly meritorious research projects consistent with our strategic imperatives:

  • Defeat lung cancer
  • Improve the air we breathe so it will not cause or worsen lung disease
  • Reduce the burden of lung disease on patients and their families
  • Eliminate tobacco use and tobacco-related lung diseases

Applications due December 15, 2016             

  Epidemiology Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 12/15/16)

Epidemiology Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

These awards are expected to provide funds that will support investigators pursuing epidemiological research aimed at improving our understanding of childhood cancer. This grant mechanism is designed to support the research that focuses on the epidemiology, early detection or prevention of childhood cancer; or comparative effectiveness and outcomes research related to detection, prevention and treatment.

Eligible areas of investigation using an epidemiological approach include the following:

  1. Epidemiology and etiology of childhood cancer (identify subgroups at risk, cause and risk factors)
     
  2. Early Detection of childhood cancer (reduce disease severity and complications e.g. screening)
     
  3. Prevention of childhood cancer (prevent initial development of disease, e.g. immunization, reduce exposure)
     
  4. Comparative effectiveness and outcomes research (evaluate existing or new preventative/therapeutic measures to improve health outcomes for children with cancer or evaluate access to treatment)
     
  5. Molecular epidemiology studies (identify contribution of potential genetic risk factors to late effects of treatment, within families and across populations)

Applications due December 15, 2016

  Independent Investigator Awards: Lung Cancer Discovery Award | American Lung Association (Deadline: 12/15/16)

Independent Investigator Awards: Lung Cancer Discovery Award | American Lung Association

The ALA offers annual funding opportunities as a part of its Awards and Grants Program. The goals of the Program are as follows:

  1. To foster laboratory, patient-centered and social-behavioral research designed to prevent and relieve the suffering associated with all lung diseases and corresponding risk factors.
     
  2. To fund researchers at important crossroads of their careers to gain long-term commitment to lung disease research.

The objective of the Lung Cancer Discovery Award is to support clinical, laboratory, epidemiological or any other kind of research projects aimed at:

  • Discovering novel approaches in improving clinical methods for the early detection of lung cancer or improving knowledge on the benefits of lung cancer screening.
     
  • Developing novel medical treatments, advancing current treatment options or finding a cure for lung cancer.

Projects are expected to have a direct impact on early detection/treatment methods or provide a clear conceptual or experimental foundation for future development. The preference is for studies that are likely to result in patient benefit in the near future.

Applications due December 15, 2016

  Lung Health Dissertation Grant (LH) | American Lung Association (ALA) (Deadline: 12/15/16)

Lung Health Dissertation Grant (LH) | American Lung Association (ALA)

The objective of this grant is to support pre-doctoral dissertation research in the various disciplines of social science examining risk factors affecting lung health including:

- Psychosocial research
- Behavioral research
- Health services and health policy research
- Epidemiology / Biostatics research
- Public Health Education research

Applications due December 15, 2016

  Senior Research Training Fellowship (RT) | American Lung Association (ALA) (Deadline: 12/15/16)

Senior Research Training Fellowship (RT) | American Lung Association (ALA)

The objective of this award is to support first time training of recently graduated MDs and PhDs seeking further academic training as scientific investigators researching the mechanisms of lung disease and general lung biology.

The Lung Association is particularly interested in highly meritorious research projects consistent with our strategic imperatives:

  • Defeat lung cancer
  • Improve the air we breathe so it will not cause or worsen lung disease
  • Reduce the burden of lung disease on patients and their families
  • Eliminate tobacco use and tobacco-related lung diseases

Applications due December 15, 2016

  Social-Behavioral Research Grant (SB) | American Lung Association (ALA) (Deadline: 12/15/16)

Social-Behavioral Research Grant (SB) | American Lung Association (ALA)

This grant is a mentored award is meant to provide seed monies to junior investigators on the path to independence for working within the various disciplines of social science examining risk factors affecting lung health including:

  • Psychosocial research
  • Behavioral research
  • Health services and health policy research
  • Epidemiology / Biostatics research
  • Public Health Education research

Applications due December 15, 2016

  HVTN Research and Mentorship Program (RAMP) Scholar Program for African-American and Latino/a Medical Students (Deadline: 1/4/17)

HVTN Research and Mentorship Program (RAMP) Scholar Program for African-American and Latino/a Medical Students

HVTN, in collaboration with the National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases, is investing in the next generation of HIV prevention researchers by providing African American and Latino/a medical students with opportunities for independent research along with structured mentoring, project and salary funding, training, and professional development activities.

Program Tracks

Grant recipients will work under the mentorship of HVTN-affiliated investigators to conduct research projects in areas of basic, clinical, behavioral and social science. Projects can be:

Short-Term

  • Can be timed with a summer break or fourth year research elective
  • Travel to an HIV Vaccine Trials Unit in the US or abroad
  • Attend and present at an HVTN Conference

Long-Term

  • Research at an HIV Vaccine Trials Unit in the US with up to 16 weeks at an international HIV Vaccine Trials Unit
  • Can be timed with a planned Master's or doctoral program, or be a distinct, non-degree associated research-focused year
  • Attend two scientific conferences, including presenting at the HVTN conference

Applications due January 4, 2017

  Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology - Independent Investigator and Consortium Grant | Rally Foundation for Childhood Cancer Research (Deadline: 1/10/17)

Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology – Independent Investigator and Consortium Grant | Rally Foundation for Childhood Cancer Research

Collaborative Pediatric Cancer Research Awards Program members include Rally Foundation, Bear Necessities, Arms Wide Open Childhood Cancer Foundation, and The Truth 365, national non-profit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaboration may choose to co-fund or individually fund an applicant.

Funding is available for research fellowships. The Collaboration invites proposals for funding of projects in the following areas:

  • Basic Science Research
  • Clinical Translational Research
  • Alternative Therapy Studies (using natural agents, integrated, personalized or holistic approaches)
  • Survivorship and Palliative Care Studies

Rally funds research in the following areas:

  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

Letter of Intent due October 13, 2016

Applications due January 10, 2017

  ABTA Research Collaboration Grants | American Brain Tumor Association (Deadline: 1/11/17)

ABTA Research Collaboration Grants | American Brain Tumor Association

The ABTA Research Collaboration (ARC) Grants are two-year, $200,000 grants intended to promote team science in a way that will streamline and accelerate progress and effect the desired change in clinical outcome for brain tumors. The research projects supported under this mechanism must be conducted by a team of at least two co-principal investigators (Co-PI's) from distinct institutions. The research project should be multi-disciplinary in that it incorporates multiple components such as basic, translational, clinical and epidemiological research.

Letter of Intent due October 5, 2016

Applications due January 11, 2017

  Clinical Investigator Award | Society of Surgical Oncology (SSO) (Deadline: 1/17/17)

Clinical Investigator Award | Society of Surgical Oncology (SSO)

The purpose of this award is to promote patient-oriented research conducted by surgical oncologists in clinical and translational science. The Foundation requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus. Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group.

Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers.

Applications due January 17, 2017

  Childs Memorial Fund for Medical Research | Jane Coffin (JCC Fund) (Deadline: 2/1/17)

Childs Memorial Fund for Medical Research | Jane Coffin (JCC Fund)

The Fund was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The Fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers.

Applications due February 1, 2017

  Clinic and Laboratory Integration Program (CLIP) | Cancer Research Institute (Deadline: 2/1/17)

Clinic and Laboratory Integration Program (CLIP) | Cancer Research Institute

CLIP Grants provide funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support basic, pre-clinical, and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic.

Letter of Intent due November 1, 2016

Applications due February 1, 2017

  Research Grant Program: A-T Post Doctoral Fellowship Award (Deadline: 3/1/17)

Research Grant Program: A-T Postdoctoral Fellowship Award

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available.

The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on:

  • translational (bench to bedside) research
  • clinical studies

Applications due March 1, 2017

  Specialized Center of Research Program | Leukemia & Lymphoma Society (Deadline: 3/1/17)

Specialized Center of Research Program | Leukemia & Lymphoma Society

LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Applications due March 1, 2017

  Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 3/6/17)

Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

The overall objectives of this grant are to advance cell and gene therapy into the causes, treatment and prevention of all types of cancer by promoting development of novel and innovative studies by young investigators. The emphasis of this initiative is to promote basic and pre-clinical research approaches utilizing cells and genes as medicine. ACGT will direct its grants into areas of cell and gene therapy research that have demonstrated great promise.

The seven main areas of research ACGT will support are:

  1. Tumor-Specific Replicating Viruses and Bacteria
  2. Anti-angiogenesis
  3. Immune-modulatory Therapy and Cancer Vaccines
  4. Oncogene/Suppressor Oncogene/Apoptosis Directed Therapy 9
  5. Tumor Targeting and Vector Development
  6. Cancer Stem Cell Directed Therapy
  7. Other Gene/Cell based Therapies

Applications due March 6, 2017

  PSC Partners Seeking a Cure (Deadline: 4/1/17)

PSC Partners Seeking a Cure

PSC Partners Seeking a Cure is a 501(c)(3) nonprofit organization whose mission is to provide education and support to PSC patients, families and caregivers and to raise funds to research causes, treatments and cures for primary sclerosing cholangitis. PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD), ulcerative colitis (UC) or Crohn's disease) as they relate to PSC. The applicant must be at an academic institution with an interest in pursuing PSC as an indication for treatment. The purpose is to encourage investigators to conduct research in promising new areas with the goal that data generated will lead to federal (NIH) funding.

PSC Partners Seeking a Cure is particularly interested in funding research projects that have the potential to discover a cure for this disease, and/or identify novel therapies that may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC. PSC Partners understands that much fundamental research is necessary to discover the environmental factors that may trigger this disease in genetically susceptible individuals, and therefore we would like to encourage research proposals aimed at identifying the gene-environment interactions contributing to disease initiation and progression. PSC Partners recognizes that studies with animal models may be appropriate to address these fundamental questions. We are interested in funding research that explores PSC-related diseases (IBD, UC, and Crohn's disease) in ways that they impact, enable, or perhaps cause PSC. PSC Partners encourages research that will be complementary to the goals and objectives of the International PSC Study Group, including investigation of the functional roles of genes associated with susceptibility to and severity of PSC. Other priority areas for research include the mechanisms of PSC pathogenesis and colorectal and cholangiocarcinoma carcinogenesis as well as strategies for prevention. Applications focused on assessing and improving the quality of life of PSC patients are also encouraged. Proposals that have little relevance to PSC will not be considered for funding. We strongly encourage interdisciplinary collaborations and the sharing of resources as a means of accelerating progress in PSC research. If the proposal includes a specific plan for sharing of results and resources (such as DNA), this will result in a more favorable review. Applications addressing PSC in children are strongly encouraged.

Applications due April 1, 2017

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline: Continuous

Top